Matrix Latest Target In Teva’s Zoloft Battle

Law360, New York (February 7, 2007, 12:00 AM EST) -- India’s Matrix Laboratories Ltd. has become the latest target of Teva Pharmaceuticals Industries Ltd. in the Israeli generic drug maker’s wide-ranging patent infringement lawsuit over its exclusive rights to sell a generic version of Pfizer Inc.’s blockbuster depression drug Zoloft.

Teva filed the suit Friday in the U.S. District Court for the District of New Jersey. The complaint alleges that Secunderabad-based Matrix plans to supply sertraline hydrochloride, the active pharmaceutical ingredient in Zoloft, to one or more generics makers who plan to market copies of the...
To view the full article, register now.